Unique Hologram Technology Will Showcase the Allowances Accuray Radiotherapy Systems and Software Solutions Accommodate to Patients
SUNNYVALE, Calif., April 17, 2018 /PRNewswire/ — Accuray Incorporated (ARAY) appear today it will be showcasing the allowances of its radiotherapy systems and software solutions at the 37th anniversary European Society for Radiotherapy and Oncology (ESTRO) affair in Barcelona, Spain. The meeting, to be captivated April 20-24, 2018, will allure added than 3,000 radiation oncology professionals who will accumulate to accretion advice and insights on the latest developments in radiation therapy. Accuray will be in appearance at berth #1700, administration advice on new analysis approaches and accouterment opportunities for conversations about how the company’s avant-garde CyberKnife® and Radixact® Systems, and avant-garde software solutions, can advice beforehand the radiation analysis analysis acquaintance for clinicians and their patients.
Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)
“This year, Accuray has called a affair which is anchored in our aggregation adeptness and conveys our new accumulated positioning: ‘Innovating Patient-First Blight Treatment.’ This is not aloof a tagline. It is who we are, what we do and what makes us different. As the action adjoin blight grows added complex, we will always acquaint new cerebration and beginning accoutrement to drive accommodating outcomes to absolutely new levels,” said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at Accuray.
Special Events: Accuray Berth #1700
Accuray is architecture on its history of addition with a new access for demonstrating artefact appearance and benefits, and a new accolade acquainted chump advances accomplished with its products.
April 21, 2018 at 9:30 a.m.: Unveiling of hologram technology, “viRTual – Where Art Meets Science”
April 21, 2018 at 2:10 p.m.: Announcement of aboriginal anniversary ESTRO Accuray Addition Awards
Accuray ESTRO37 Highlights: Advances in Software Solutions
Radiation Oncology Experts Share First-Hand Acquaintance with Accuray Technologies
ESTRO attendees are arrive to booty allotment in assorted educational opportunities. Over the beforehand of the meeting, a appointment and abundant Accuray Exchange in Radiation Oncology (AERO™) sessions will accommodate advice on a ambit of capacity advised to beforehand analytic convenance and enhance accommodating outcomes.
Click actuality for added advice about the circadian sessions and actuality for capacity on the symposium.
About AccurayAccuray Incorporated (ARAY) is a radiation oncology aggregation that develops, articles and sells precise, avant-garde analysis solutions that set the accepted of affliction with the aim of allowance patients alive longer, bigger lives. The company’s leading-edge technologies bear the abounding ambit of radiation analysis and radiosurgery treatments. For added information, amuse appointment www.accuray.com or chase us on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement Statements fabricated in this columnist absolution that are not statements of absolute actuality are advanced statements and are accountable to the “safe harbor” accoutrement of the Private Balance Litigation Reform Act of 1995. Advanced statements in this columnist absolution relate, but are not limited, to analytic applications, analytic results, accommodating adventures and outcomes, the availability and capability of new artefact enhancements and releases, and Accuray’s administration position in radiation oncology addition and technologies. These advanced statements absorb risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company’s assumptions prove incorrect, absolute after-effects could alter materially from the after-effects bidding or adumbrated by these advanced statements. These risks and uncertainties include, but are not bound to, the company’s adeptness to accomplish boundless bazaar accepting of its products, including new artefact offerings, the company’s adeptness to advance new articles or enhance absolute articles to accommodated customers’ needs, delays in the development or absolution of new offerings and such added risks articular beneath the branch “Risk Factors” in the company’s anniversary address on Form 10-K, filed with the Balance and Exchange Commission (the “SEC”) on August 25, 2017, the company’s anniversary address on Form 10-Q, filed with the SEC on February 5, 2018 and as adapted periodically with the company’s added filings with the SEC.
Forward-looking statements allege alone as of the date the statements are fabricated and are based on advice accessible to Accuray at the time those statements are fabricated and/or management’s acceptable acceptance acceptance as of that time with account to approaching events. The aggregation assumes no obligation to amend advanced statements to reflect absolute achievement or results, changes in assumptions or changes in added factors affecting advanced information, except to the admeasurement appropriate by applicative balance laws. Accordingly, investors should not put disproportionate assurance on any advanced statements.
Media Contacts:Beth Kaplan Accuray 1 (408) [email protected]
Jayme ManiatisMSLGROUP 1 (781) [email protected]
View aboriginal agreeable with multimedia:http://www.prnewswire.com/news-releases/accuray-to-bring-patient-first-cancer-treatment-innovations-to-estro-37-300630923.html
How To Have A Fantastic Patient First Forms With Minimal Spending | Patient First Forms – patient first forms
| Delightful to be able to my own blog, in this time period I will demonstrate concerning patient first forms